Evolving catalytic antibodies in a phage-displayed combinatorial library.

I Fujii; S Fukuyama; Y Iwabuchi; R Tanimura

doi:10.1038/nbt0598-463

Home/Archive/PubMed

PubMed · 9592396

Evolving catalytic antibodies in a phage-displayed combinatorial library.

I Fujii·S Fukuyama·Y Iwabuchi·R Tanimura

View original source ↗Export metadata ↓

Abstract

In vitro affinity maturation for evolving catalytic antibodies has been demonstrated by generating a diverse repertoire of the appropriate complementarity-determining regions on a phage surface. Phage display is followed by a selection based on binding to an altered antigen that was not used at the time of immunization, and provides variants with new catalytic activity and substrate specificity. This library format reduces the time needed to isolate the desired catalytic antibody fragments to under 2 weeks.

Explore related subjects

Antibodies, Catalytic Bacteriophages Binding, Competitive Enzyme-Linked Immunosorbent Assay Evolution, Molecular Gene Library Immunoglobulin Fab Fragments Immunoglobulin Variable Region Models, Molecular Molecular Mimicry Mutation Oligonucleotides Plasmids Protein Engineering Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

I Fujii, S Fukuyama, Y Iwabuchi, R Tanimura. 1998. Evolving catalytic antibodies in a phage-displayed combinatorial library.. https://doi.org/10.1038/nbt0598-463

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Computer-aided rational design of catalytic antibodies: The 1F7 case.

Explore the source record for details and available documents.

Antibodies, Catalytic↗

PubMed2006

Toward bifunctional antibody catalysis.

Antibodies that catalyze the deprotonation of unactivated benzisoxazoles to give the corresponding salicylonitriles were prepared using as antigen a 2-aminobenzimidazolium derivative coupled to a carrier protein via its benzene ring. The hapten was designed to induce an antibody binding site with both a base and an acid, in position to initiate proton transfer and stabilize developing negative charge at the phenoxide leaving group, respectively. Consistent with this design, the catalysts exhibit bell-shaped pH-rate profiles, while chemical modification identified several functional groups that could participate in bifunctional catalysis. One of the antibodies, 13G5, is particularly notable in catalyzing the elimination of 6-glutaramidebenzisoxazole with a > 10(5)-fold rate acceleration over background and an effective molarity of > 10(4) M for its catalytic base. These properties compare favorably to the efficiencies achieved by the best previously characterized antibodies with substantially more reactive substrates.

Antibodies, Catalytic↗

PubMed2006

Catalytic autoantibodies in clinical autoimmunity and modern medicine.

Abzymes (catalytic autoantibodies) belong to an absolutely new group of physiologically active substances with dual characteristics: they represent a pool of canonical autoantibodies and possess catalytic activity. Among them, proteolytic and DNA-hydrolyzing autoantibodies are of special value. Abzymes are an important pathogenic factor in the progression of clinical autoimmunity syndrome. The presence of autoantibodies against various autoantigens is accompanied by their high catalytic potential. The increase in this activity correlates with serum levels of the autoantibodies, clinical manifestations of autoimmune disorders, disease severity and the rate of progressing disability. Abzymes are crucial for immune homeostasis regulation. They can be of practical value in the development of modern immunodiagnostic tools and schedules of immunotherapy.

Antibodies, Catalytic↗